Due: 2024-02 IND-enabling Studies for Platform Clinical Trials of Genome Editing in Multiple Diseases

DUE: February 22, 2024

The purpose of this NOFO is to provide support for applications for IND-enabling studies for the development of a novel in vivo genome editing therapeutic platform (genome editor plus delivery system) for two or more disease indications, using the same genome editor, route of administration, and delivery system.